Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $51.4KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
I-Mab is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Xu Cong Claire | SVP, Clinical Development | Jul 06 '26 | Sale | $0.89 | 4,485 | $3,992 | 298,101 | Jul 07 07:50 PM |
| Dennis Phillip Andrew | Chief Medical Officer | Jun 18 '26 | Sale | $0.66 | 8,494 | $5,606 | 157,941 | Jun 22 05:23 PM |
| Xu Cong Claire | SVP, Clinical Development | Jun 01 '26 | Sale | $3.94 | 3,494 | $13,766 | 290,154 | Jun 02 06:46 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.